Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
Stephen Checkley(AstraZeneca (United Kingdom)), Claus Bendtsen(Quantitative BioSciences)
Cited by 69
Related Papers
A functional analysis of 180 cancer cell lines reveals conserved intrinsic metabolic programs
|Molecular Systems Biology|2022|36
Epithelial-mesenchymal transition is the main driver of intrinsic metabolism in cancer cell lines
|bioRxiv (Cold Spring Harbor Laboratory)|2021|2